Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $97.16M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 2.55M
Average 2.44M
STIM Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Neuronetics, Inc.NASDAQ: STIM
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $197K (cash outflow) fell 10.0% year over year, ahead of the -40.5% change in trailing-twelve-month capital expenditures. Sequentially, it fell 8.8% from the prior quarter. Over 3 fiscal years it compounded at -37.4% a year.
Context
- Capital expenditures amounted to 0.5% of revenue in FY2025, down 1.4 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -10.0% holds above the trailing-twelve-month pace of -40.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (801K) USD
- Year-over-year change
- +45.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (801K) | +45.4% |
| FY2024 | 2024-12-31 | (1.47M) | +38.1% |
| FY2023 | 2023-12-31 | (2.37M) | +27.5% |
| FY2022 | 2022-12-31 | (3.27M) | -38.9% |
| FY2021 | 2021-12-31 | (2.35M) | — |
Capital Expenditures vs competitors
How STIM compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -40.5% is the 4th highest of 8, against a peer median of -54.8%.
- Capital expenditures amounts to 0.5% of revenue for STIM, versus a peer median of 1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.95M USD | -70.1% | +248.2% | 2419.3% | |
| LTM Mar 2026 | $4.69M USD | +77.8% | -96.0% | 4.1% | |
| LTM Mar 2026 | $3.39M USD | -23.5% | -18.7% | 4.3% | |
| LTM Mar 2026 | €1.32M EUR | -65.8% | -63.4% | 8.1% | |
| LTM Mar 2026 | $779K USD | -40.5% | -37.4% | 0.5% | |
| LTM Mar 2026 | $523K USD | -54.8% | -68.0% | 1.8% | |
| LTM Mar 2026 | $208K USD | — | -68.0% | 0.2% | |
| LTM Mar 2026 | $179.08K USD | — | — | 0.9% | |
| LTM Mar 2026 | $115K USD | -56.9% | -82.8% | 0.3% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $66.77K USD | -9.1% | +18.6% | 0.0% |
| Peer median (excluding STIM) | — | -54.8% | -65.7% | 1.8% | |
Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.73M) | (39.14M) |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.87M | 8.75M | 7.32M | 5.6M | 6.85M |
| Change in Working Capital | (6.64M) | (5.12M) | (14.1M) | (6.81M) | 6.58M |
| Accounts Receivables | (3.05M) | (6.66M) | (8.83M) | (3.73M) | 3.54M |
| Inventory | (3.44M) | (2.59M) | (1.1M) | 3.15M | (395K) |
| Accounts Payables | 276K | (1.97M) | 2.03M | (1.99M) | (1.75M) |
| Other Working Capital | (415K) | 6.1M | (6.2M) | (4.25M) | 5.18M |
| Other Non-Cash Items | 918K | 1.14M | 2.93M | 11.86M | 1.87M |
| Operating Cash Flow | (27.98M) | (30.74M) | (32.04M) | (31M) | (20.37M) |
| Capital Expenditures | (2.35M) | (3.27M) | (2.37M) | (1.47M) | (801K) |
| Acquisitions (Net) | 0 | 0 | 0 | (2.55M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 324K | 0 | 0 | 0 | (31K) |
| Other Investing Activities | (7.81M) | 10M | 1.05M | 1.61M | 31K |
| Investing Cash Flow | (9.84M) | 6.73M | (1.32M) | (2.41M) | (801K) |
| Debt Repayment | 0 | 0 | 23.8M | (2.52M) | 9.62M |
| Common Stock Issued | 80.97M | 0 | 0 | 0 | 26.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.03M | 207K | (1.1M) | (4.29M) | (594K) |
| Financing Cash Flow | 83.01M | 207K | 22.7M | (6.81M) | 35.85M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 45.18M | (23.8M) | (10.66M) | (40.22M) | 14.68M |
| Free Cash Flow | (30.34M) | (34.01M) | (34.41M) | (32.46M) | (21.18M) |
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.